ViTToria Biotherapeutics Raises Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapy Lead Candidate, VIPER-101
ViTToria is focused on developing novel CAR-T cell therapies that transcend the limitations of current cell therapies.
Vivodyne Raises $38 Million Seed Financing For Development of Lab Grown Human Tissue Platform
Penn spinout Vivodyne closed a $38 million seed funding round led by Khosla Ventures.
Cabaletta Bio Receives Another FDA Clearance for IND application of CABA-201
The company plans to initiate a Phase 1/2 clinical trial of CABA-201 in two cohorts of patients with generalized myasthenia gravis (gMG).
Heirloom Opens First Commercial Carbon Capture Plant in the U.S.
Heirloom uses a process called direct air capture to remove greenhouse gases from the atmosphere.
First canine patient receives Vetigenics’ fully canine anti-CTLA4 monoclonal antibody
Vetigenics announced that the first canine patient has received his first dose of Vetigenics' fully canine anti-CTLA4 monoclonal antibody (VGS-001) for oral melanoma.
Cabaletta Bio Receives FDA Clearance of CABA-201 Investigational New Drug Application for Treatment of Generalized Myasthenia Gravis
Cabaletta Bio received FDA clearance for their fourth Investigational New Drug application of CABA-201, their CAR T cell investigational therapy, to treat patients with generalized myasthenia gravis.
Penn spinout Interius Biotherapeutics raises another $21.5M
Co-founded by Saar Gill, MD, PhD, Interius is developing a new platform for cell-specific gene delivery in patients.
FloBio Receives the FDA’s Breakthrough Device Designation for its Bleeding Risk Diagnostic Test
FloBio's test determines blood clotting status and identifies whether a patient is on popular blood thinners called Direct Oral Anticoagulants (DOACs).
Opus Genetics Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
Penn spinout Opus Genetics announced that the first patient has been dosed in its Phase 1/2, first-in-human clinical trial of OPGx-LCA5.
Penn Spinout Heirloom Technologies and Microsoft Sign One of the Largest Permanent CO2 Removal Deals To-Date
Microsoft signed a long term contract to purchase up to 315,000 metric tons of CO2 removal over a multi-year period from Penn spinout Heirloom Carbon Technologies.